How has Spyre Therapeutics, Inc.'s derivative liability, current changed year-over-year?

Spyre Therapeutics, Inc.'s derivative liability, current increased by 17.4% year-over-year, from $42.81M to $50.26M.

Spyre Therapeutics, Inc. SYRE Derivative Liability, Current

BiogenBIIB

——

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Market cap$7.67B+307%

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Spyre Therapeutics, Inc.'s derivative liability, current?: Spyre Therapeutics, Inc. (SYRE) reported derivative liability, current of $50.26M in Q1 2026.
How has Spyre Therapeutics, Inc.'s derivative liability, current changed year-over-year?: Spyre Therapeutics, Inc.'s derivative liability, current increased by 17.4% year-over-year, from $42.81M to $50.26M.